In response to the observed heterogeneity in CRC immunity, Galon et al. proposed the “Immunoscore”—a quantitative assessment of CD3+ and CD8+ T-cell densities in the tumor core and invasive margin—which has demonstrated superior prognostic value over traditional TNM staging (Pagès et al., 2018). Here, CD8A is linked to neoplasm.